13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002043476
Total reported value
$213.0M
$213.0M
16 檔
42.7%
According to the latest 13F quarterly dataset, B Group, Inc. managed an equity portfolio of $213.0M at the end of Q4 2025, spanning 16 distinct U.S. exchange-listed positions.
In Q4 2025, B Group, Inc. adopted a defensive or profit-taking posture, trimming 2 positions and completely liquidating 6 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ADMA | Adma Biologics Inc | Stock-Healthcare | 33.10% | -8.61% | +1.87% | |
| 2 | CLLS | Cellectis - Adr | Stock-Other | 11.73% | -3.09% | — | |
| 3 | PALI | Palisade Bio Inc | Stock-Other | 7.81% | -3.61% | — | |
| 4 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 7.31% | -0.21% | — | |
| 5 | PRAX | Praxis Precision Medicines I | Stock-Other | 7.23% | -2.72% | +5.51% | |
| 6 | SGHT | Sight Sciences Inc | Stock-Other | 5.39% | -0.99% | -1.08% | |
| 7 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 5.21% | -2.26% | — | |
| 8 | GPCR | Structure Therapeutics Inc | Stock-Other | 4.62% | -1.03% | — | |
| 9 | ASMB | Assembly Biosciences Inc | Stock-Other | 4.41% | -1.34% | — | |
| 10 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 3.02% | -0.97% | — | |
| 11 | SYRE | Spyre Therapeutics Inc | Stock-Other | 2.42% | -0.82% | — | |
| 12 | AURA | Aura Biosciences Inc | Stock-Other | 2.30% | -0.41% | — | |
| 13 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.29% | +0.02% | — | |
| 14 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.68% | +0.62% | — | |
| 15 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.11% | -0.47% | EXIT | |
| 16 | REPL | Replimune Group Inc | Stock-Other | 0.36% | -0.15% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ADMA | Adma Biologics Inc | +7.1% | +1.87% | Add |
| 2 | PRAX | Praxis Precision Medicines I | +6% | +5.51% | Add |
| 3 | CLLS | Cellectis - Adr | +4.9% | — | Unchanged |
| 4 | SGHT | Sight Sciences Inc | +3% | -1.08% | Trim |
| 5 | TSHA | Taysha Gene Therapies Inc | +3% | — | Unchanged |
| 6 | SYRE | Spyre Therapeutics Inc | +1.2% | — | Unchanged |
| 7 | ASMB | Assembly Biosciences Inc | +1.1% | — | Unchanged |
| 8 | IOVA | Iovance Biotherapeutics Inc | +0.6% | — | Unchanged |
| 9 | ORKA | Oruka Therapeutics Inc | +0.6% | — | Unchanged |
| 10 | REPL | Replimune Group Inc | +0.2% | — | Unchanged |
| 11 | APGE | Apogee Therapeutics Inc | +0.1% | -42.86% | Trim |
| 12 | AURA | Aura Biosciences Inc | -0.3% | — | Unchanged |
| 13 | RARE | Ultragenyx Pharmaceutical In | -0.7% | — | Unchanged |
| 14 | ZLAB | Zai Lab Ltd-adr | -4.8% | — | Unchanged |
| 15 | LLY | Eli Lilly & Co | — | EXIT | Sold out |
| 16 | NVDA | Nvidia CORP | — | EXIT | Sold out |
| 17 | AKRO | Akero Therapeutics Inc | — | EXIT | Sold out |
| 18 | PALI | Palisade Bio Inc | — | NEW | New buy |
| 19 | GPCR | Structure Therapeutics Inc | — | NEW | New buy |
| 20 | ✓ | Nrx Pharmaceuticals Inc | — | EXIT | Sold out |
| 21 | GAME | Gamesquare Holdings Inc | — | EXIT | Sold out |
| 22 | INSM | Insmed Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, B Group, Inc. reported a total U.S. public equity portfolio value of $213.0M across 16 disclosed positions in Q4 2025.
During Q4 2025, B Group, Inc.'s top holdings by market value included ADMA (33.1%)、CLLS (11.7%)、PALI (7.8%). The largest single position, ADMA, represented 33.1% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ADMA, CLLS, PALI) accounted for 42.7% of total reported equity market value during Q4 2025.
Top New Position Initiated
PALI
市值: $10.6M
Top Position Liquidated / Trimmed
LLY
前期市值: $17.2M
In Q4 2025, B Group, Inc. made 12 total portfolio adjustments, initiating 2 new buys, adding to 2 positions, trimming 2 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.